IA
PTGX icon

IFP Advisors’s Protagonist Therapeutics PTGX Stock Holding History

IFP Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Hold
0
– – – 3681
2025
Q1 		– Sell
-5
Closed -$193 – 4566
2024
Q4 		$193 Buy
+5
New +$218 ﹤0.01% 3767
2021
Q3 		– Sell
-8
Closed – – 3439
2021
Q2 		$0 Sell
8
-34
-81% -$1.12K ﹤0.01% 3191
2021
Q1 		$1K Buy
42
+2
+5% +$51 ﹤0.01% 2864
2020
Q4 		$1K Buy
+40
New +$861 ﹤0.01% 2806

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IFP Advisors's PTGX Position: Q2 2025 in Review

IFP Advisors held its Protagonist Therapeutics (PTGX) position steady in Q2 2025 at 0 shares worth $3.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3681.

IFP Advisors first reported a position in PTGX in Q4 2020 and has held it in 4 quarters since. The position peaked at $1K in Q1 2021. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • IFP Advisors held 0 shares of Protagonist Therapeutics worth $3.1K as of Q2 2025.
  • IFP Advisors left its Protagonist Therapeutics share count unchanged in Q2 2025.
  • Protagonist Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2025, its #3681 holding.
  • IFP Advisors first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • IFP Advisors's Protagonist Therapeutics position peaked at $1K in Q1 2021.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.